Introduction
Stress myocardial perfusion scintigraphy (myocardial scan) is frequently used for cardiovascular (CV) risk stratification in the general population. In patients with chronic kidney disease (CKD), however, the utility of the method has been questioned due to its reduced sensitivity in this particular population [1, 2] . Still, encouraging results have been occasionally reported [3] [4] [5] , suggesting that the subject merits further evaluation. We reason that the disparate results in the literature could be caused by differences in patient selection. To test that hypothesis, we assessed the prognostic value of the myocardial scan in a group of patients with advanced CKD on the waiting list for transplant with different clinical risk profiles. We assumed that the identification of subgroups of CKD patients who will or will not benefit from the test would have a significant clinical and economic impact on patients' workup, especially for those on the transplant waiting list.
Materials and methods

Subjects
This was a single-center cohort study performed in a group of consecutive hemodialysis patients undergoing pre-transplant CV assessment. The study was approved by the Institutional Ethics Committee and conducted according to the Declaration of Helsinki [6] . Eight hundred and ninetytwo renal transplant candidates (>18 years old), listed to receive their first kidney graft from a deceased donor at the Renal Transplant Unit, Division of Urology, University of São Paulo Medical School, were referred to the Heart Institute (InCor) for CV assessment. All patients were being treated by maintenance hemodialysis, performed in 4-h sessions, three times per week using a bicarbonate bath and with a minimum target Kt/V of 1.3.
Study protocol
A comprehensive clinical and CV investigation was performed including dipyridamole myocardial stress testing by SPECT with 99mTc-sestamibi in all subjects. Abnormal myocardial stress testing was defined as either transient or fixed defects. Qualitative analysis in the myocardial perfusion imaging with dipyridamole stress testing included 17 segments. The areas of defects were calculated using left ventricular mass as reference, as following: minimal < 5%, small 5-9%, intermediate 10-19% and large ≥20%. Fixed perfusion defects were considered as fibrosis, whereas transient hypoperfusion was interpreted as ischemia. All patients underwent SPECT myocardial perfusion imaging with 99mTc-sestamibi or 201Tl. Image acquisition began 45-60 min after sestamibi injection at rest (dose 370 MBq) and stress (dose 800 MBq) and 4 h after stress (redistribution image) with a single-detector gamma camera system equipped with low-energy high-resolution collimator. All studies were performed with the following parameters: 64 projections; 180°non-circular orbit, 45°right anterior oblique to left posterior oblique angles; matrix size, 64 × 64 and pixel size, 6.7 mm. Images were reconstructed by filtered back projection with a Butterworth filter (order, 5; cutoff frequency, 0.6 Nyquist) and resliced into short-axis, vertical long-axis and horizontal long-axis views that were used for qualitative analysis.
Patients had a 12-lead resting electrocardiogram and a transthoracic echocardiogram as part of their evaluation. Hypertension was defined as (millimeter of mercury) systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg (average of three consecutive readings taken between two consecutive dialysis sessions). Dyslipidemia was defined as total cholesterol and/or triglycerides ≥200 mg/dL. We used the Framingham study as a reference to define hypercholesterolemia. Because there is no guideline to define hypertriglyceridemia in dialysis patients, we used the median of our data. Diabetes (Types 1 and 2) was defined according to American Diabetes Association Guidelines [7] . CV disease was defined by at least one of the following: heart failure, previous myocardial infarction or stroke, coronary intervention (surgical/ percutaneous) and arterial vascular disease. Heart failure was defined as New York Heart Association functional Class III or IV or ejection fraction < 40%, myocardial infarction by characteristic electrocardiographic and enzyme alterations and stroke, by clinical/radiological evidence. The diagnosis of arterial vascular disease was based on clinical grounds (absence of pulse in one or more peripheral arteries), a history of amputation or vascular intervention or both. Patients with angina were not included. All subjects, independently of clinical risk stratification, were maintained on statins, aspirin, angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers) and β-blockers according to current guidelines for secondary prevention of CV events [8] , as previously reported [9] . Patients were followed from the time of placement on the waiting list until death, renal transplantation or occurrence of CV events.
Clinical risk stratification
Patients were classified into four risk groups according to the modification of the American Society of Transplantation index [10] that used age ≥50 years, diabetes (Types 1 or 2) and clinical CV disease to define the risk of future adverse events as follows: low risk-no risk factors, intermediate risk-one factor (either age, diabetes or CV disease), high risk-two risk factors in any combination and very high risk-all three factors present.
Clinical end points and follow-up
The mean follow-up for the whole group was 26 ± 20 months (median 22 months). The primary endpoint was the composite incidence of major CV events (fatal/non-fatal) defined as sudden death, acute coronary syndromes (unstable angina or myocardial infarction), stroke, life-threatening arrhythmia, heart failure and acute peripheral artery disease requiring intervention. When more than one event occurred, only the first event was considered for analysis. The secondary end point was death from any cause. The causes of events and deaths that did not occur at our center were established by interviewing patients, their families or their attending physicians or by a death certificate (when available). Routine autopsies were not performed.
Statistical analysis
Data analyses were performed with commercially available statistical software (SPSS version 13; SPSS Inc., Chicago, IL). The results are presented as means ± SD of means unless otherwise stated. The differences between groups were assessed by Fisher's exact test for categorical variables or the Student's t-test or median tests for continuous data. Cox regression models were used to investigate the association of clinical stratification and CV events and death. Survival curves were constructed by using the Kaplan-Meier method and compared by log-rank. A Pvalue < 0.05 was considered statistically significant. Table 1 shows the main characteristics of the groups. The prevalence of patients in the low-, intermediate-, high- and very high-risk groups was 21, 37, 28 and 15%, respectively. Comparisons among variables were not performed because they were used as criteria for group classification.
Results
During the follow-up, 181 major CV events were observed (overall incidence = 20%): 12 (6.6%) in low-risk, 51 (28.2%) in intermediate-risk, 61 (33.7%) in high-risk and 57 (31.5%) in very high-risk patients (P < 0.0001, Figure 1 ). Cardiac events (myocardial infarction = 36, unstable angina = 23, sudden death = 35, pulmonary edema needing hospitalization = 21, heart failure = 9, life-threatening arrhythmia = 5 and pulmonary emboli = 1) occurred in 130 patients (72%). In 51 patients (28%), non-cardiac events (stroke = 33 and acute peripheral arterial disease = 18) were observed. Table 2 shows the prevalence of altered myocardial scan in the four clinically defined risk groups. The prevalence of abnormal scan increased with the degree of risk, from 12.7% in low-risk patients to 50.8% among very high-risk subjects. Figure 2A -D shows the composite incidence of major CV events (fatal/non-fatal), as assessed by myocardial scan, in the four clinical risk groups. Only in patients with one risk factor (either age ≥50 years, diabetes or CV disease) was an altered myocardial stress test associated with an increased incidence of major CV events [30.3 versus 10%, hazard ratio (HR) = 2.37, confidence interval (CI) 1.69-3.33, P < 0.0001]. Low-risk patients did well regardless of the results of the myocardial scan; on the other hand, in patients with 2 or 3 risk factors, the finding of an altered stress test did not add to the already increased risk for future CV events. The composite incidence of major cardiac events (fatal/ non-fatal), calculated after excluding patients who developed either stroke or acute peripheral artery disease requiring intervention, was evaluated in the four clinical risk groups. We found that the results of myocardial scan were relevant only in patients with one risk factor (P < 0.001, HR = 1.62, CI 1.19-2.21).
We also considered the association of altered myocardial scan with the composite incidence of major CV events in diabetics and non-diabetics. In diabetics, the prevalence of altered myocardial scan in patients with and without events was 36 and 27%, respectively (P = 0.38, HR = 1.54, CI 0.94-2.53), whereas in non-diabetics, the correspondent figures were 27 and 11%, respectively (P = 0.001, HR = 3.12 CI 1.96-4.96). However, the role of diabetes per se in this context is difficult to establish since diabetes is frequently associate with aging and with CV disease.
During the follow-up, 163 patients died (18%). Overall mortality was also influenced by clinical and myocardial scan stratification. The incidence of death by any cause was 4.8% (low risk), 17% (intermediate risk), 24% (high risk) and 24% (very high risk), P < 0.0001. When clinical risk stratification was combined with the results of the myocardial perfusion scan, an abnormal scan had an adverse effect on the long-term all-cause mortality rate only in patients with one single risk factor (HR = 2.8, CI 1.5-5.1, P = 0.007). For patients with none, two or three risk factors, the all-cause mortality rate was independent of the results of the myocardial perfusion scan.
Discussion
The study tests how CV risk profiles affect the ability of non-invasive myocardial perfusion tests to predict CV events and death in patients with advanced renal disease on the waiting list for renal transplantation. The main finding of our study is that myocardial stress testing is useful to define risk only in patients with one of the risk factors selected by the 'American Society of Transplantation'. Our results indicate that the test is reliable provided that it is applied only after careful clinical risk stratification. They also offer a reasonable explanation for the disparate results in the literature concerning the performance of myocardial scintigraphy in patients with CKD.
We found that roughly 40% of patients will benefit from the test, while patients with no risk factors or with more than one risk factor will not. The results indicate that myocardial scans could be avoided in at least 60% of asymptomatic patients with end-stage renal disease on the waiting list. On the other hand, restricting myocardial scan to non-diabetics will avoid the test in no more than 40% of patients since the prevalence of diabetics on the transplant waiting list is close to 35% worldwide [11, 12] . It should be stressed, however, that our investigation was not designed to compare different methods to select patients for myocardial scan. Our aim was to demonstrate that the system we developed fulfills its objectives and that makes sense economically.
There is no definitive explanation for the reduced sensitivity of myocardial scan in patients with CKD. It has been speculated that the phenomenon could be related to the increased circulating levels of adenosine in some patients with kidney failure [13] . Concurrent reduced coronary flow reserve and left ventricular hypertrophy may also play a role. More likely, in patients with multiple or severe comorbidities, like CV diseases, this or any other similar test will add little to the already very high probability of future events. Indeed, it is well recognized that, in general, tests conceived for risk stratification will perform better in subjects with intermediate probability to develop events instead of in those already known to be at very high or at very low risk of events. In that regard, our observations confirm previous reports [14, 15] showing that extensive CV evaluation is unnecessary in asymptomatic low-risk patients and that risk stratification based exclusively on clinical grounds predicts major adverse events.
Should all Groups 2 and 3 patients be assessed by coronary angiography along with Group 1 patients with an abnormal myocardial scan? The study was not conceived to verify the best strategy for invasive investigation in patients with CKD and any conclusion in that regard should be considered with caution, in spite of encouraging evidence reported with the use of coronary angiography for CV assessment in renal transplant candidates [1, [16] [17] [18] . Moreover, it is unlikely that information from invasive test will add to the already accentuated CV risk of Groups 2 and 3 patients. Therefore, we believe that coronary angiography should be performed in those patients mainly for clinical or therapeutic reasons and not for risk stratification.
In conclusion, our investigation is of interest because it introduces a simple, reliable evidence-based method to identify, among patients at risk, those more likely to benefit from a myocardial scan, avoiding unnecessary testing in roughly 60% of patients on the transplant waiting list. In addition, the results may also help to elucidate why myocardial scanning is reported to perform well in renal patients in some investigations but gives disappointing results according to others.
We acknowledge the limitations of our investigation. This was a single-center study that included only patients on the waiting list. Also, non-invasive testing was not repeated unless clinically warranted, limiting our ability to follow the progression of the disease. We did not extend our observations to the post-transplant period. Finally, the study was not conceived to verify the best strategy for invasive investigation in patients with CKD and any conclusion in that regard should be considered beyond the scope of the present work.
